DOCSLIB.ORG

1 GLAXOSMITHKLINE ACCELERATING OUR STRATEGY: GSK to ACQUIRE FULL OWNERSHIP of CONSUMER HEALTHCARE BUSINESS Tuesday, 27 March

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 GLAXOSMITHKLINE ACCELERATING OUR STRATEGY: GSK to ACQUIRE FULL OWNERSHIP of CONSUMER HEALTHCARE BUSINESS Tuesday, 27 March GLAXOSMITHKLINE ACCELERATING OUR STRATEGY: GSK TO ACQUIRE FULL OWNERSHIP OF CONSUMER HEALTHCARE BUSINESS Tuesday, 27 March 2018 Analyst Call @ 14.00 hrs Balbir Kelly-Bisla (Director of Investor Relations): Good morning and good afternoon everyone. Thank you for joining us to discuss the transaction we announced earlier today. You should have received our press release and can view the presentation on GSK's website. For those not able to view the webcast, slides that accompany today's call are located on the Investor section of the GSK website. Cautionary statement regarding forward-looking statements Before we begin, please refer to slide 2 of our presentation for our cautionary statements. Agenda Our speakers today are Chief Executive Officer, Emma Walmsley, Simon Dingemans, Chief Financial Officer, and Brian McNamara, CEO of our Consumer Healthcare business. Following our presentation, we will open the call to questions and answers. We request that you ask only a maximum of two questions so that everyone has a chance to participate and with that I will hand the call over to Emma. Emma Walmsley (CEO): Thank you, Balbir, and a very good morning and good afternoon to everybody. Balanced business to deliver growth and returns to shareholders I am delighted to be here to discuss the announcement we made earlier today on the agreement to buy out Novartis' stake in our Consumer Healthcare joint venture. A strategic strength for GSK is our business profile beyond Pharma, the sustainable growth, returns and cashflows. Today's agreement strengthens one of our three global businesses and will support overall performance and capital planning for the group. Advancing our priorities Last year, I laid out my strategic priorities: Innovation, Performance and Trust, and our capital allocation framework. This transaction that we have announced today is 1 consistent with both those priorities and this framework. Through full ownership of the Consumer Healthcare business, we aim to deliver improved performance. Very importantly, the transaction removes an inherent uncertainty for the group with the removal of the Novartis put option. This will allow us to plan use of our capital for other priorities, especially Pharma R&D. As I have said, strengthening and investing in our Pharma pipeline is critical to support the company for its next wave of growth and we expect to give a first update to the market on our R&D plans at Q2. Two important milestones for Consumer Healthcare The buyout of the Novartis stake means GSK's shareholders will capture the full value of a business we believe is well positioned to deliver future sales growth and continued operating margin improvements. As Brian will come on to explain in a moment, we are confident that the investments and changes we have made to this business in recent years, building new power brands, a stronger focus on OTC and Oral Health, improved innovation capability, increased focus on digital, new operational efficiencies and, of course, building a great team, all mean we have a winning business. To support the funding of the Novartis buyout, we are also announcing a strategic review of Horlicks and other Consumer Healthcare nutrition products. Horlicks is a terrific brand with a long history especially in India but, in the context of funding for this transaction and our desire to increase focus on our OTC and Oral Health portfolios, as well as other group capital allocation priorities, it makes sense for us to review it. Given that the vast majority of Horlicks sales are sold through our Indian subsidiary, GlaxoSmithKline Consumer Healthcare Limited, which is a listed company in which we are the majority shareholder, the strategic review will include an assessment of this shareholding. We would expect the outcome of this review to be concluded around the end of 2018. It is very important to emphasise that India remains a priority market for GSK. Consumer Healthcare will continue to invest in growth opportunities for its OTC and Oral Health brands in the country such as Sensodyne and Eno, and we are actively investing in our Pharmaceuticals and Vaccines businesses, notably with a new state-of-the-art manufacturing facility in Vemgal, Karnataka. Let me now hand over to Simon first who is going to talk through the financial highlights of this transaction. 2 Simon Dingemans (Chief Financial Officer): Thank you, Emma. Financial highlights Today's announcement to buy out Novartis' stake in our Consumer Healthcare joint venture for a consideration of £9.2 billion, marks the final leg of the three-part transaction we first announced with Novartis in 2015. As part of that transaction, we formed a highly successful joint venture and, whilst we have had a very good relationship with our partner, we have always said we would like to own the rest of the business. We like the market and the categories we are in. We think their prospects are good and that our portfolio of leading brands is well placed to generate attractive returns. Additionally, we like Consumer cash flows in the mix of the group as they are inherently more stable and balance the significant other investments we have to support, including the R&D pipeline. The valuation for the buyout was negotiated in a way that was consistent with the methodology set out in the existing Joint Venture Shareholders Agreement, which specifies that the joint venture should be valued as if it were a separate publically traded company with no premium applied. It also reflects our latest views and forecasts for the expected profits of the joint venture. The agreed price of £9.2 billion is around 3% different to the undiscounted valuation we included in the year-end accounts of £8.9 billion, well within normal trading ranges. Including the buyout, the joint venture has generated a double digit return and met our CFROI target since its formation. Looking at the direct financial effects, the transaction will be accretive to earnings in 2018 and thereafter and will strengthen our free cash flow. We have also combined the transaction with a strategic review of the Horlicks business and other Consumer nutrition products. This is designed to keep us within our target credit profile, further protecting our access to capital markets and allowing us to continue to invest behind our other capital allocation priorities. As Emma has said, for us, the transaction removes uncertainty and enables shareholders to capture the full value of the business. With 100% ownership, we now have full control to develop this business how we think best in the future. We continue to expect operating margins of more than 20% by 2020, in 2015 exchange rate terms but we see opportunity for further margin enhancement beyond that. 3 Brian will talk you through some of the drivers in more detail in a moment but we expect to see operating margins for the Consumer Healthcare business approaching the mid-20s percentages by 2022 at 2017 exchange rates. As I have said, the transaction is accretive to earnings in 2018 but we are not changing our guidance for the year today as we still need to navigate whether or not we see an Advair generic. As you will remember, we gave guidance for growth in adjusted EPS in constant exchange rate terms if there was no generic of 4-7% in 2018 and if there was a launch mid-year of flat to down 3%. We will update you when we have more clarity on this but most likely not before the middle of the year. Looking towards our 2020 outlooks, the financial benefits of the transaction further support our increased confidence to drive growth over the next two to three years and to deliver against these outlooks whilst at the same time having the flexibility to invest in the group’s other capital allocation priorities, particularly R&D. On the dividend, we continue to expect to pay 80p per share for 2018. There is no change to our dividend policy, which you will remember is based on free cash flow cover. We expect the buyout to be accretive to free cash flow. Timing and considerations Moving to timing and other considerations, as Novartis is a related party to GSK we are required to put the buyout transaction to a shareholder vote. We expect that to happen swiftly within the next few months with closing expected to occur around the middle of the year. On the strategic review of Horlicks and the other Consumer Healthcare nutrition products, we would expect to conclude that process around the end of 2018. The brands being reviewed amounted to sales of approximately £550 million in 2017, most of which relate to sales of Horlicks in India. The review will also involve an assessment of the group’s shareholding in our publically listed Indian subsidiary business and we will be consulting with their Board on this process. Now let me hand you over to Brian. 4 Brian McNamara (CEO Consumer Healthcare): Thank you, Simon. Global leader in Consumer Healthcare With the investment in the Novartis put we now have full ownership of a world- leading Consumer Healthcare business. As a reminder, GSK Consumer Healthcare delivered £7.8 billion in net sales in 2017, roughly a quarter of the group turnover. This is a business with attractive returns and strong cash flows. We have a very strong portfolio with seven Power brands, 11 Core brands, allowing us to compete effectively across our broad geographic footprint. Even excluding the nutrition business under review, over 35% of our business is in emerging markets. We have a strong track record of execution delivering a sales growth CAGR of 4% over the past three years driven by high single-digit growth of our Power brands and at the same time growing margin 670 basis points to 17.7% in 2018.
Load more

Recommended publications
  • The Everyday Lives of Recovering Heroin Users
    The everyday lives of recovering heroin users Joanne Neale Sarah Nettleton Lucy Pickering The everyday lives of recovering heroin users The everyday lives of recovering heroin users Joanne Neale Sarah Nettleton Lucy Pickering Joanne Neale Professor of Public Health Faculty of Health & Life Sciences Oxford Brookes University Jack Straw’s Lane Marston Oxford OX3 0FL Email: [email protected] Sarah Nettleton Reader in Sociology Department of Sociology Wentworth College University of York Heslington York YO10 5DD Email: [email protected] Lucy Pickering Lecturer in Anthropology School of Social and Political Sciences University of Glasgow Adam Smith Building Glasgow G12 8RT Email: [email protected] Published by the RSA 8 John Adam Street London WC2N 6EZ +44 (0)20 7930 5115 Registered as a charity in England and Wales no. 212424 and in Scotland no. SCO 37784 Copyright © Joanne Neale 2012 The RSA is an enlightenment organisation devoted to finding innovative and practical solutions to today’s pressing social problems Cover photo: ‘Wings of butterfly,’ John Foxx. © Thinkstock Designed by Soapbox, www.soapbox.co.uk Printed and bound by CPI Antony Rowe www.theRSA.org Contents Acknowledgements 9 Foreword 10 Chapter 1: Setting the scene 14 Why read this book? 14 Why focus on recovery? 15 What is recovery? 15 A study of the everyday lives of recovering heroin users 17 Structure of the book 18 Chapter 2: Considering recovery 20 Introduction 20 Mapping services and support 20 Factors that can encourage and sustain recovery efforts
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Quite Often , a Jar of Horlicks Occupies a Visible Position in a Bangladeshi
    www.horlicks.com Quite often, a jar of Horlicks occupies a visible position in a Bangladeshi household. Successive generations of the country over the past half century have consumed it- stirred in as glass of hot milk or water- and become totally confirmed believers in Horlick's virtues of good health and nutrition. I t is a nutritional drink made from wheat, milk and malted barley and contains essential vitamins and minerals for wholesome nourishment of the entire family. Horlicks, ' The Great Family Nourisher' is the leading Health Food Drink in the country. Today, the modern Horlicks stands for trust and it s promise of ' Pleasurable Nourishment'. For over a century now Horlicks has provided a strong nourishment platform to both children and adults and believes that this nourishment platform can be a key enabler in helping an individual maximize his/her potential. Market Product Worldwide, the major markets of Horlicks are: U.K., Put a couple of tablespoons full into a mug; add India, Hong Kong, Australia and New Zealand, warm water or milk and you're ready to enjoy a Caribbean, Central America, Middle East, Africa, drink that's tasty and nourishing. Horlicks is also Pakistan, Asia. available in chocolate flavour, which combines the benefits of Horlicks nourishment and a wonderful After India, the 2nd biggest market for Horlicks in new taste. Add ice cubes, cold milk or water to Asia region is Bangladesh, where it has traditionally been marketed as 'The Great Family Nourisher, until 2007. Since 2007, with a new product promise, "Horlicks makes kids Taller, Stronger, Sharper- Now proven" it has positioned itself as a special nutritional drink for kids aged between 6 - 14 years.
    [Show full text]
  • Your Kidneys and What They Do
    Chapter Headings CHAPTER HEADINGS The Library is split into several chapters click on the section you require for more information + 1.Your Kidneys & What They Do + 2. Diseases & Conditions + 3. Treatments & Investigations + 4. Peritoneal Dialysis + 5. Haemodialysis + 6. Transplant + 7. Living With Kidney Disease + 8. Support Services + 9. Diet + 10. Drugs + 11. Research + 12. Glossary file:///C|/Program Files/My stuff/Back from Eiddwen Updated WKPL Files/Chapter Headings/chapter_headings_main.htm09/12/2009 10:21:57 CHAPTER HEADINGS CHAPTER 2 DISEASES & CONDITIONS This section has more than one leaflet please choose the leaflet you wish to view by clicking the blue underlined text + 2. Diseases & Conditions - Alport's Syndrome - Analgesic Nephropathy - Autosomal Dominant Polycystic Kidney Disease - Diabetes and Kidney failure - Glomerulonephritis - Gout and Kidney patients - High Blood Pressure - Hyperparathyroidism & renal bone disease - IgA Nephropathy file:///C|/Program Files/My stuff/Back from Eiddwen Updated WKPL Files/Chapter Headings/chapter_headings_section2.htm (1 of 2)08/12/2009 15:36:38 CHAPTER HEADINGS - Lupus - Systemic Lupus Erythematosus - Myeloma - Nephrotic Syndrome - Obstructive Uropathy - Pain-killers & the kidney - Pyelonephritis - Simple Cysts - Urinary Tract Infection - Vasculitis file:///C|/Program Files/My stuff/Back from Eiddwen Updated WKPL Files/Chapter Headings/chapter_headings_section2.htm (2 of 2)08/12/2009 15:36:38 Alport’s Syndrome Alport’s Syndrome What is Alport’s Syndrome? Alport’s Syndrome is an inherited condition that causes abnormal development of the kidney. This abnormal development allows damage to occur to the capillary membranes of the glomeruli. These structures act as filters, removing excess water and waste from the blood. The damage is gradual and leads to kidney failure.
    [Show full text]
  • Self Study Report Ii Cycle
    The ICFAI Foundation for Higher Education (Declared as Deemed-to-be University under Section 3 of the UGC Act, 1956) Donthanapally, Shankarapalli Road Hyderabad – 501 203, Telangana. Tel: 040 – 23479999 Website: http://www.ifheindia.org e-mail:[email protected] Fax: 08417 – 236653 SELF STUDY REPORT II CYCLE Submitted to The Director National Assessment and Accreditation Council (NAAC) Nagarbhavi, Bangalore – 560 072, Karnataka January – 2015 TABLE OF CONTENT Profile of the University 7 Milestones 25 NAAC Peer Team Recommendations 2009 27 Action Taken Report – NAAC Peer Team Recommendations 2009 31 Action Taken Report –UGC Review Committee Recommendations 2009 39 Executive Summary 47 Criteria-Wise Inputs Criterion I: Curricular Aspects 69 Criterion II: Teaching-Learning and Evaluation 98 Criterion III: Research, Consultancy and Extension 155 Criterion IV: Infrastructure and Learning Resources 262 Criterion V: Student Support and Progression 286 Criterion VI: Governance, Leadership and Management 349 Criteria VII: Innovations and Best Practices 389 Shri N. J. Yasaswy (1950 – 2011) Founder The ICFAI Group Shri N.J.Yasaswy, the founder of the ICFAI Group of Educational Institutions was a pioneer and trailblazer in promoting higher education in the Private Sector. He conceptualized, developed and built competitive and top graded Business schools in India apart from creating 11 Universities in the developing states of India (including in the North East) single-handedly. He wanted to nurture and groom young students - who had the will to learn but were unable to gain entry into the premier management institutes for a variety of reasons. He built a Temple of Learning offering value based education, industry- focused curriculum and employable skills.
    [Show full text]
  • What Will Novartis Do with $13Bn Cash Pile from GSK?
    6 April 2018 No. 3899 Scripscrip.pharmaintelligence.informa.com Pharma intelligence | informa Eric Le Berrigaud, an analyst at Bryan Gar- nier, said in an investor note March 27 that $13bn “is a touch above our estimated trans- action price.” He added that the sale will provide Novartis “with more financial flexibil- ity to be used exceptional share buy-backs or access to more strategic alternatives i.e. broadening the range of targets for potential bolt-on acquisitions fitting its core business- es.” It is “strategically good for Novartis given that it simplifies and focuses its organization.” Analysts at Deutsche Bank noted that the deal would be dilutive to the tune of around 3.5% per year to core earnings per share un- less Novartis deploys the cash elsewhere. They wrote that “disappointingly, the company is vague in this regard, discussing only its stan- dard capital allocation policy, rather than any Shutterstock: Nomad_Soul Shutterstock: pre-prepared statement for a commitment to reduce the dilution through a share buy back. As such, Novartis management has the abil- What Will Novartis Do With $13bn ity to create shareholder value through this transaction but the jury remains out for now.” The jury appears to be in at Société Gé- Cash Pile From GSK? néral, where analysts issued a note say- KEVIN GROGAN [email protected] ing that the $13bn price tag “is a positive surprise” as they had valued the stake at ovartis AG CEO Vas Narasimhan capital to grow our core businesses, drive $10.6bn. They wrote that they expect Nara- has only been in the hot seat for a shareholder returns and execute value-cre- simhan “to refocus the company on innova- Ncouple of months but is wasting no ating bolt-on acquisitions.” Narasimhan also tion,” believing that Novartis will give more time in transforming the firm into a pure stressed his often-repeated message about details about its plans to redeploy the cash pharma player, selling its stake in a con- building “the leading medicines company, with its first quarter results on April 19.
    [Show full text]
  • Glaxosmithkline Annual Report 2010
    Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Business review 2010 Performance overview 08 Research and development 10 Pipeline summary 12 Products, competition and intellectual property 14 Regulation 18 Manufacturing and supply 19 Business review World market 20 This discusses our financial and non-financial activities, GSK sales performance 21 resources, development and performance during 2010 Segment reviews 22 and outlines the factors, including the trends and the Responsible business 29 principal risks and uncertainties, which are likely to Financial review 2010 34 affect future development. Financial position and resources 41 Financial review 2009 47 Governance and remuneration Risk factors 53 This discusses our management structures and governance procedures. It also sets out the Governance and remuneration P58–P101 Governance and remuneration Governance and remuneration remuneration policies operated for our Directors and Our Board 58 Corporate Executive Team members. Our Corporate Executive Team 60 Governance and policy 64 Financial statements Dialogue with shareholders 69 The financial statements provide a summary of the Internal control framework 71 Group’s financial performance throughout 2010 and its Committee reports 74 position as at 31st December 2010. The consolidated Remuneration policy 84 financial statements are prepared in accordance with Director terms and conditions 91 IFRS as adopted by the European Union and also IFRS as Director and Senior Management remuneration 94 issued by the International Accounting Standards Board. Directors’ interests 96 Directors’ interests in contracts 101 Shareholder information This includes the full product development pipeline and discusses shareholder return in the form of dividends and share price movements.
    [Show full text]
  • LOVE of FOOD-08092020.Cdr
    ISSUE 01 Vol. 01 EDITION 1 - SEPTEMBER 2020 QUICK RECIPES DELICIOUSLY HEALTHY MEET OUR BE FUTURE CHEFS READY A CULINARY JOURNEY OF OUR INHOUSE SODEXO IS CONTINUOUSLY LOOKING AT CHEFS THESE CREATIVE YOUNG MINDS WAYS INTO ADAPTING OUR FOOD ARE TRANSFORMING SODEXO’S SERVICES TO MEET OUR CLIENT AND CULINARY LANDSCAPE AND CONSUMER'S REQUIREMENT REIMAGINING HOW DINERS EAT OUT THROUGHOUT THIS CHALLENGING TIME. CREATIVITY & INNOVATION HAS ALWAYS BEEN THE FOCAL POINT OF OUR WORK 1. FROM THE DIRECTOR’S DESK 2. MEET OUR CHEF’S Ronald Minezes - Head, Portfolio & Services Development Ashwin Iyangar - Sr Project Manager, Culinary Services Shobhit Mohan - Menu Program Manager, DRIVE Puneet Khanna - Retail Head, Education 3. QUICK RECIPES - Deliciously Healthy 4. HOT WOK - Innovation Unchallenged 5. BE FUTURE READY 6. MEET THE FOOD PLATFORM TEAM from the DIRECTOR'S DESK Welcome to the 1st edition of the Love of Food E-Book, India. As we enter We have come up with a unique food per specic client requirement by our team of the 6th year of transformation of Food Services at Sodexo our Food solutions wherein the menu has been curated Chefs. Experts and SME’s have developed innovative Food Offers, Mouth by our chefs keeping in mind current Watering Culinary Recipes and Best in Class Services to enhance the requirements in a changed environment, As we move forward, we see a second overall experience for our clients and consumers. Love of Food has always ensuring that the menu is not labor intensive transformation and focus towards getting our been at the center of what we do in the Food Platform, supporting four and requires minimum human intervention.
    [Show full text]
  • GSK Thwarts the Attempted “Scooping” of Its HORLICKS Trademark
    GSK Thwarts the Attempted “Scooping” of its HORLICKS Trademark March 13, 2019 By Amrita V. Singh The Federal Court of Canada has rejected an application by Bedessee Imports Ltd., an importer and distributor of food products, including beverages, drinks and drink mixes, to expunge GlaxoSmithKline’s (“GSK”) longstanding HORLICK’S and HORLICKS trademark registrations. HORLICKS branded malted milk powder was originally developed for children and people with health ailments, and later became known as a meal replacement drink. It is widely sold internationally.[1] Bedessee brought its application in 2017, claiming that the HORLICK’S and HORLICKS marks were not registrable when they were registered, were not distinctive, and had been abandoned. In 2017, Bedessee had also filed its own proposed use application for HORLICKS in association with “malted milk powder drink mix, drinks,” and other goods. GSK’s evidence showed that its Canadian consumer healthcare business, which is and was responsible for the HORLICKS products, has imported the HORLICKS products and then distributed them through Canadian grocery stores, retail stores and specialty markets. GSK’s evidence also showed that its worldwide sales of HORLICKS products in 2017 exceeded $600 million USD. The HORLICKS Marks were Registrable when Registered In support of its position that the HORLICKS Marks were not registrable when registered, Bedessee pointed to a dictionary definition from 1907 for “Horlick’s Food”, ten years before the registration date, which the Court found irrelevant to its assessment of registrability in 1917. Bedessee also relied upon historic advertisements prior to 1917 purporting to use HORLICKS generically, and argued the advertisements could prove a mark is descriptive or generic.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • Trainer Guide: Training of LAC Counsellors
    TRAINING OF LAC COUNSELLORS TRAINER’S GUIDE Care, Support & Treatment Division Basic Services Division Department of AIDS Control (NACO) Ministry of Health and Family Welfare Government of India 2012 1 Acknowledgments Contributors: Dr. Melita Vaz Programme Officer (Counselling) Ms Sumitha Chalil Technical Officer (Counselling) Ms Nisha Kadyan Technical Officer (Nursing) Reviewers: Though the reviewers are not known to the team of contributors, their inputs helped to shape the early draft copy. Also Dr. B.B. Rewari National Programme Officer (ART) Dr. Reshu Agarwal Programme Officer (CST) Field Testing: Counsellors of Andhra Pradesh Dr. Christopher Nathan Regional Co-ordinator, Andhra Pradesh Dr. Po-Lin Chan World Health Organisation Dr. Tarak Shah Centers for Disease Control Prof. Harilakshmi Andhra University, Vishakhapatnam (Saksham Project) Special Contribution: Saksham Project for permission to adapt the Kaun Banega Sanjeev Kapoor exercise Dr. Suresh Shastri for photographs on a Child-Friendly LAC ART Centre team at BJMC, Ahmedabad, Gujarat 2 Table of Contents Page No Acknowledgments 2 Table of Contents 3 Introduction to the training package 5 Sample Programme Schedule 6 Sessions at a Glance 7 Note about the Development of this Package 9 Note for SACS 10 Pre-Post training questionnaire 12 Pre-Post training questionnaire Answer key 18 Reporting sheet for Item 23 20 Session 1: Understanding the Link ART Centre 21 Session 2: Counselling at the Link ART Centre 28 Session 3: Basics of Antiretroviral therapy 31 Session 4: Opportunistic Infections and their Management 38 Session 5: Adherence Counselling at the Link ART Centre 39 Session 6: Adherence Counselling for Children at the Link ART Centre 54 Session 7: Teaching the Use of the Adherence Calculator 73 Session 8: Nutrition Counselling 79 Session 9: Pre-ART Care 88 Session 10 89 Annexures 90 3 4 Introduction Who does the training package address? This package addresses the capacity development needs of counsellors working at Link ART Centres.
    [Show full text]